Compare Davita Inc (DVA) vs Okta, Inc. (OKTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Okta, Inc. — how do they compare? Davita Inc trades at $178.34 (market cap $11.72B), while Okta, Inc. trades at $152.4 (market cap $26.20B). The key difference: Okta, Inc. is far larger — about 2.2× Davita Inc's market cap, and Okta, Inc. is trading nearer its 52-week high, Davita Inc nearer its low. Which is the better fit depends on your goals.
| DVA | OKTA | |
|---|---|---|
Market Cap | $11.72B | $26.20B |
Sector | Health | Technology |
52-Week High | $240.96 | $154.62 |
52-Week Low | $103.87 | $62.93 |
Enterprise Value | $24.44B | $24.03B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $183.77, up 1.72% today, with a mixed technical picture showing bearish moving averages but bullish oscillators. The company reported strong Q2 2026 earnings of $4.02 per share, beating estimates, driven by volume growth. Revenue reached $13.64 billion in 2025, with a net income margin of 6.05%. Analyst consensus is a Buy with a $232.25 price target, though technical signals are bearish overall.
The outlook for DVA is cautiously optimistic, supported by earnings beats and volume growth, but risks include reimbursement pressure and high debt levels. The stock offers potential upside to the consensus target, yet investors face headwinds from margin compression and technical bearishness.
OKTA trades at $148.32, up 3.35% today, near its recent high of $157.00. The stock shows bullish momentum with consistent earnings beats, including Q1 2026 EPS of $0.91 versus $0.853 expected. Revenue growth is robust, rising from $1.3B in 2022 to $2.6B in 2025, with net income turning positive at $28M. Technical indicators signal bullish trends, while analyst consensus is strongly positive with 72.55% buy ratings.
Outlook is favorable due to strong cybersecurity demand and AI-driven product launches, but risks include high valuation (P/E of 107.48) and competition. Upside potential exists if earnings growth continues, with a consensus price target of $127.96 suggesting caution relative to current price. Investors should monitor Q2 2026 results on August 26, 2026, for confirmation of profitability trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →
